BMS at AAD VMX 2021
Intended for U.S. scientific audiences only.
he American Academy of Dermatology’s (AAD) Virtual Meeting Experience (VMX) 2021 is an important opportunity for scientific exchange on research and breakthroughs for patients living with dermatologic diseases. We look forward to showcasing new research and sharing progress for patients with immune-mediated diseases.
Hear from Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, about Bristol Myers Squibb’s presence at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) and the company’s commitment to patients living with psoriasis and other immune-mediated diseases.
Our Data at AAD VMX 2021
Read more about our key data being presented at the meeting.
We are committed to improving the lives of patients with immune-mediated diseases, like psoriasis, and remain steadfast in exploring additional potential treatment options that might provide benefit for patients where unmet need still exists. Learn more here.
Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.
Our research in Immunology and dermatology follows a science-driven pathway approach that delivers scientific innovation across key areas of focus.